Tags
- 2025
- A
- Acquisition
- Adalimumab
- Agent
- All In
- Allocation
- Approved
- Autoinjector
- Based on
- Benefit
- BioScience
- Biosciences
- Biosimilar
- Bolster
- Branded
- Branded product
- Brutal
- Buyer
- Cancer immunotherapy
- Cash
- Cash position
- Chairman
- Characteristic
- Chicago
- Chief
- Chief executive
- Chief executive officer
- Chinese
- Chinese company
- Coherus BioSciences
- Commerce
- Commercial activities
- Communal work
- Competition
- Deal
- Deals
- Denny Lanfear
- Denosumab
- Development
- D.O.E.
- Drug
- Earn
- End
- Executive
- Executive officer
- Existence
- Exit
- Exits
- Expect
- Focus
- Formulation
- Founding
- Franchise
- Generic
- Generic drug
- Growth
- Health
- Health system
- Hong Kong
- Hospital
- Indication
- Inhibitor
- Injection
- Injector
- In-phase and quadrature components
- Insulin
- Insulin aspart
- Insulin glargine
- Insulin lispro
- Judgement
- Keep
- Kong
- Kroger
- Limiter
- Lot
- Manufacturing
- Market
- Maximum
- Maximum value
- Need
- New
- Novel
- Officer
- Oncology
- Over
- Payer
- Pegfilgrastim
- Pharmaceutical drug
- Pharmacy
- Pharmacy benefit management
- Phase
- Phase 1
- Phases of clinical research
- Pipeline
- Portfolio
- Position
- Prediction
- Prefilled syringe
- Press release
- Proceed
- Product
- Programmed cell death protein 1
- Purchase
- Ranibizumab
- Reinforcement
- Require
- Research
- Research and development
- Resource
- Sale
- Salesforce.com
- Sandoz
- Sell
- Some
- Stable
- Stake
- Still
- Strategy
- Subsidiary
- Substantial
- Sustain
- Sustainability
- Syringe
- Systems
- Take Over
- The Desire
- The end
- Therapy
- Today
- Trial
- Value proposition
- Who